Back to Search
KENNETH PIENTA, MD
MD
Medical Oncology Physician
NPI: 1649356510Individual
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
4301058498(MI)
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
4301058498(MI)D36665(MD)
Education
JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
Class of 1986
Research & Publications (20)
Prostate cancer promotes CD11b positive cells to differentiate into osteoclasts.
PMID 19170075·J Cell Biochem·2009
8-other
Microfluidic system for formation of PC-3 prostate cancer co-culture spheroids.
PMID 19304321·Biomaterials·2009
7-preclinical
Possible mechanism of CCL2-induced Akt activation in prostate cancer cells.
PMID 19661323·Anticancer Res·2009
8-other
A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone.
PMID 19176388·Cancer Res·2009
7-preclinical
Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy.
PMID 19366804·Cancer Res·2009
8-other
Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later.
PMID 19375622·Urology·2009
6-review
Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model.
PMID 19259948·J Cell Biochem·2009
7-preclinical
Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02.
PMID 18990504·Int J Radiat Oncol Biol Phys·2009
3-trial
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data.
PMID 19213602·Lancet Oncol·2009
8-other
Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer.
PMID 18636554·J Cell Biochem·2008
8-other
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.
PMID 18829513·Clin Cancer Res·2008
8-other
CCL2 induces prostate cancer transendothelial cell migration via activation of the small GTPase Rac.
PMID 18646053·J Cell Biochem·2008
8-other
Molecularly targeted radiosensitization of human prostate cancer by modulating inhibitor of apoptosis.
PMID 19047096·Clin Cancer Res·2008
7-preclinical
Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments.
PMID 19043526·Transl Oncol·2008
8-other
Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa.
PMID 18645028·Mol Cancer Ther·2008
7-preclinical
CCL2, survivin and autophagy: new links with implications in human cancer.
PMID 18758234·Autophagy·2008
8-other
Tumor expressed PTHrP facilitates prostate cancer-induced osteoblastic lesions.
PMID 18729185·Int J Cancer·2008
7-preclinical
Re: RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastasis model.
PMID 18792431·Eur Urol·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 600 N WOLFE ST, ONCOLOGY 123
BALTIMORE, MD 21287 - Phone
- (410) 283-1016
Quick Facts
- NPI
- 1649356510
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 3
- Locations
- 1
- Years in Practice
- 40
- Publications
- 20
Are you this provider?
Claim Your Profile